Genprex, Inc. — Form 8-K Summary
Reporting date: October 21, 2026. Event: Item 8.01, Other Events. Genprex (Nasdaq: GNPX) announced peer-reviewed research concerning TUSC2, the gene used in its investigational REQORSA cancer gene therapy.
Business context and research
The study, “Mitochondrial calcium sensor TUSC2 protects the aging hippocampus from proteostasis collapse in a sex-specific manner,” was published in Mechanisms of Ageing and Development by researchers at Meharry Medical College. In an engineered mouse knockout model, TUSC2 loss was associated with disruption of mitochondrial function, protein homeostasis, and neuronal communication pathways in the hippocampus. Effects were more pronounced in male mice; females showed adaptive stress responses.
Analysis of existing human gene-expression datasets found that TUSC2 expression declined with age in 11 of 13 examined brain regions, with additional reductions in Alzheimer’s disease datasets. Comparisons identified molecular changes overlapping between the mouse findings and human hippocampal aging data.
Financial and operating metrics
This 8-K reports no revenue, earnings, cash flow, margins, debt, liquidity, or other financial results. It provides no prior-period comparison or financial guidance.
Outlook, commentary, and risks
Genprex said the findings broaden understanding of TUSC2’s biological functions and may support further investigation of its role in brain health. The company also noted that the results are exploratory. The study did not test REQORSA as a treatment for aging or neurodegenerative disease; Genprex describes REQORSA as under development for cancer.
The filing’s forward-looking-statement cautions include risks to clinical development timelines and outcomes, regulatory submissions and approvals, manufacturing and third-party performance, financing and long-term liquidity, continued Nasdaq listing compliance, ability to continue as a going concern, strategic initiatives, and intellectual property. The filing refers investors to the company’s 2025 Form 10-K risk factors.
Key facts for investors to verify
- The study’s findings are preclinical and based partly on analysis of existing human datasets; they do not establish a treatment benefit in people.
- REQORSA was not evaluated in the study and remains an investigational oncology product candidate.
- Check Genprex’s subsequent filings for updates on clinical programs, financing, liquidity, Nasdaq listing compliance, and any plans related to this research.